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Chemoresistance is the main obstacle to cancer cure. Contrasting studies focusing on sin-
gle gene mutations, we hypothesize chemoresistance to be due to inactivation of key path-
ways affecting cellular mechanisms such as apoptosis, senescence, or DNA repair. In
support of this hypothesis, we have previously shown inactivation of either TP53 or its
key activators CHK2 and ATM to predict resistance to DNA damaging drugs in breast cancer
better than TP53 mutations alone. Further, we hypothesized that redundant pathway(s)
may compensate for loss of p53-pathway signaling and that these are inactivated as well
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MO L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 1 5 5 3e1 5 6 41554ResistanceBreast cancergene (RB1) and its key regulators: Cyclin D and E as well as their inhibitors p16 and p27. In
an exploratory cohort of 69 patients selected from two prospective studies treated with
either doxorubicin monotherapy or 5-FU and mitomycin for locally advanced breast can-
cers, we found defects in the pRB-pathway to be associated with therapy resistance (p-
values ranging from 0.001 to 0.094, depending on the cut-off value applied to p27 expres-
sion levels). Although statistically weaker, we observed confirmatory associations in a vali-
dation cohort from another prospective study (n ¼ 107 patients treated with neoadjuvant
epirubicin monotherapy; p-values ranging from 7.0  104 to 0.001 in the combined data
sets). Importantly, inactivation of the p53-and the pRB-pathways in concert predicted
resistance to therapy more strongly than each of the two pathways assessed individually
(exploratory cohort: p-values ranging from 3.9  106 to 7.5  103 depending on cut-off
values applied to ATM and p27 mRNA expression levels). Again, similar findings were
confirmed in the validation cohort, with p-values ranging from 6.0  107 to 6.5  105
in the combined data sets. Our findings strongly indicate that concomitant inactivation
of the p53- and pRB- pathways predict resistance towards anthracyclines and mitomycin
in breast cancer in vivo.
ª 2015 The Authors. Published by Elsevier B.V. on behalf of Federation of European
Biochemical Societies. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction established that p53 (the protein encoded by the TP53 gene)Resistance towards chemotherapy remains the main reason
for treatment failure and death among cancer patients.
Considering breast cancers exposed to optimal adjuvant
chemo- and/or endocrine therapy, on average, the death
rate is reduced by about 30e50% (Albain et al., 2012). In meta-
static disease, however, the effect of therapy is temporary,
and resistance in general develops within less than one year
for each individual regimen (Alba et al., 2004; Greenberg
et al., 1996).
Despite extensive experimental research, the mechanisms
underlying resistance to chemotherapy in vivo remains poorly
understood. Regarding treatment with anthracyclines in
breast cancer, topo-II amplifications have been associated
with a dose-responsiveness different from what is observed
in non-amplified tumours (Knoop et al., 2005; Tanner et al.,
2006), but no single factor predictive of drug resistance has
reached clinical application. Breast cancers may be stratified
into different biological subgroups based on their global
gene expression profiles (Perou et al., 2000; Sorlie et al.,
2001). These subgroups differ in their mutational profile and
may respond differently to chemotherapy (Hugh et al., 2009;
Rouzier et al., 2005; Sorlie et al., 2006). However, resistance
to given therapy regimens may not be predicted based on
gene expression signatures. Rather, the results, so far, are
more consistent with the underlying mechanisms of drug
resistance being unequally distributed between the sub-
classes. Similarly, other gene expression signatures have
revealed correlations to outcome but to be modest with
respect to predicting drug resistance (Albain et al., 2010; Paik
et al., 2006; Straver et al., 2010).
To explore potential mechanisms of anthracycline resis-
tance in breast cancer, we have undertaken a different
approach, searching for defects in key functional pathways
regulating vital cellular functions like growth arrest, DNA
repair and apoptosis (Lonning et al., 2013). It is wellplays a key role in executing DNA damage induced apoptosis
and growth arrest (Enoch et al., 1995). Previously, we reported
mutations in the L2 and L3 domains of p53 to be associated
with resistance to chemotherapy with anthracycline mono-
therapy (Chrisanthar et al., 2008; Geisler et al., 2001) or mito-
mycin plus 5-fluoro-uracil in combination (Geisler et al.,
2003) and similar results have been reported by others
(Kandioler-Eckersberger et al., 2000). The finding that these
TP53mutations were highly associated with, but not fully pre-
dictive for, chemoresistance made us postulate that inactiva-
tion of other genes involved in the p53 pathway could
substitute for TP53 mutations and generate a similar chemo-
resistant phenotype (Lonning, 2004). In support of our hypoth-
esis, we found nonsensemutations in the CHEK2 gene and low
expression levels of ATM (the two factors mainly responsible
for activating p53 in response to genotoxic stress (Buscemi
et al., 2004; Chehab et al., 1999; Hirao et al., 2000)) to substitute
for TP53 mutations predicting resistance toward DNA
damaging drugs in vivo (Chrisanthar et al., 2008; Knappskog
et al., 2012).
The findings that inactivation of the p53-pathway (ATM e
CHK2 e p53) predicts resistance to chemotherapy while
similar inactivation is also observed in some chemosensitive
tumours made us hypothesize that response to therapy may
be executed through redundant pathways (Lonning, 2004;
Lonning et al., 2007). In this respect, several lines of evidence
indicate a role for the retinoblastoma protein (pRB), a key
regulator of cell cycle arrest upon DNA damage (Harrington
et al., 1998). Concomitant inactivation of p53 and pRB leads
to immortalization of keratinocytes (Smeets et al., 2011) as
well as lymphoma development and chemoresistance in a
transgenic mouse model (Schmitt et al., 2002). While muta-
tions affecting the RB1 gene are rare in breast cancer, we
have previously found such mutations associated with a
poor response to anthracycline chemotherapy in both primary
and metastatic breast cancer (Berge et al., 2010, 2011).
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pathway to predict resistance to therapy with DNA damaging
agents in patients suffering from locally advanced breast can-
cer (Figure 1). Importantly, we found concomitant inactivation
of both the p53-pathway and the pRB-pathway to be more
strongly associated with chemoresistance as compared to
inactivation of each pathway alone. Based on these findings,
we propose amodel where in vivo resistance to DNA damaging
drugs occurs as a consequence of concomitant inactivation of
both the p53- and the pRB- pathways.2. Materials and methods
2.1. Patients and evaluation of response
This study included an exploratory cohort (n¼ 69) (Knappskog
et al., 2012), containing patients from two single institution
studies combined (Geisler et al., 2001, 2003), and a validation
cohort (n ¼ 107), based on patients from a multicenter study
(Chrisanthar et al., 2008; Knappskog et al., 2012). All patients
suffered from locally advanced breast cancers. The study pro-
tocols were approved by the regional ethical committee and
all patients provided informed consent. Tumour samples
were obtained prior to chemotherapy by an open biopsy,
and all tissue samples were snap-frozen in liquid nitrogen
immediately upon excision in the operating theatre. The pa-
tients for this study were enrolled between 1991 and 2001,p53
Apoptosis
CHK2
ATM
p53-pathway
Senescence
Growth arrest
A
Figure 1 e Schematic illustrations of the p53 (therefore, the responses were consistently graded by the
UICC system (Hayward et al., 1977) and not the more recently
implemented “RECIST” criteria (Therasse et al., 2000). For
further details on response evaluation criteria and patient co-
horts, see Supplementary information.2.2. Nucleic acid purification
Genomic DNAwas isolated by using the QIAampDNAMini Kit
(Qiagen) according to the manufacturer’s instructions. Total
RNA was purified using Trizol (Life Technologies) extraction
and cDNA was synthesized by reverse transcription using
the Transcriptor reverse transcriptase system (Roche) accord-
ing to themanufacturer’s instructions, using both Oligo-T and
random hexamers as primers.2.3. Mutation screening
Point mutations and indels were analyzed for RB1, CDKN2A
(p16) and CDKN1B (p27) by PCR amplification and Sanger
sequencing. Primers and reaction conditions for RB1 and
CDKN2A were as previously described (Berge et al., 2010;
Knappskog et al., 2006). The p27 coding region (CDKN1B) was
amplified using the primer pairs listed in Supplementary
Table S1. Amplificationswere carried out using the DyNazyme
DNA EXT polymerase (FINNZYMES) according to themanufac-
turer’s instructions. For detailed protocol, see Supplementary
information.CDK2
RB
G1
M G2
S
p16INK4ap27KIP1
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A) and the pRB (B) functional pathways.
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DNA sequencing was performed using Big Dye terminator
mixture (Applied Biosystems) and capillary gel electropho-
resis on an ABI 3700 DNA sequencer (PerkineElmer Bio-
systems). For detailed protocol, see Supplementary
information.2.5. Quantitative PCR
Levels of p27 mRNA were determined using hydrolysis probe-
assays on the LightCycler 480 system (Roche). All analyses
were performed as duplex reactions amplifying the gene of in-
terest in the same reaction well as the ribosomal protein P2
(rpP2), as internal reference. All obtained Cp values were con-
verted to relative concentrations via internal standard curves
in each run. Each analysis was performed in triplicate. For
detailed protocol, see Supplementary information. ATM
mRNA levels were extracted from previously published data
(Knappskog et al., 2012).2.6. Methylation specific PCRs (MSP)
For promoter methylation analyses, genomic DNA from
tumour samples were subjected to methylated- and
unmethylated-specific PCRs, using the AmpliTaq Gold DNA
Polymerase (Applied Biosystems) after bisulfite modification
using the CpGenome DNA Modification Kit (Intergen). For
detailed protocol, see Supplementary information.2.7. Fluorescence in situ hybridization (FISH)
All samples in the exploratory cohort were analyzed for
CCND1 and CCNE1 amplifications by fluorescence in situ hy-
bridization on sections from formalin fixed and paraffin
embedded tumour tissue. Samples were scored as amplified
if the ratio between gene specific (CCND1 and CCNE1) and a
centromeric reference was higher than 2. (For detailed proto-
col, see Supplementary information).2.8. MLPA
Copy number alterations for RB1, CCND1 and CCNE1 (valida-
tion cohort) and CDKN2A were assessed by MLPA. Analyses
were performed using the SALSA MLPA RB1, the P078-Breast
tumour and the CDKN2A/2B probemix-kits respectively
(MRC-Holland, Amsterdam, The Netherlands), as previously
described (Berge et al., 2010; Knappskog et al., 2006). In brief,
in the patient samples, the peak areas of all MLPA products
resulting from probes specific for the genes of interest were
first normalized by the average of peak areas resulting from
control probes (specific for locations other than the chromo-
some harbouring the gene of interest). A ratio was then calcu-
lated where this normalized value was divided by the
corresponding value from a sample consisting of pooled
DNA from >6 healthy individuals. A sample was scored as
having a reduced copy number at a specific location if this ra-
tio was below 0.75, and as having an increased copy number if
the ratio was above 1.25.2.9. Statistical analyses
Samples were assessed for potential factors predicting drug
resistance by comparing tumours progressing on therapy
(PD) to the combined group of tumours classified as SD/PR/
CR (responders), as previously described (Chrisanthar et al.,
2008; Geisler et al., 2003, 2001; Knappskog et al., 2012). The
theoretical rationale for this approach has been outlined in
detail elsewhere (Lønning, 2003).
For TP53, mutations affecting the L2/L3 domains (including
nonsense and frameshiftmutations upstreamof the sequence
encoding these domains) were included in themodel based on
previous findings (Chrisanthar et al., 2008; Geisler et al., 2003,
2001; Knappskog et al., 2012). For CHEK2, mutations previously
found to maintain wild-type kinase activity were excluded
(Chrisanthar et al., 2008). Since the thresholds for what may
be regarded as pathologically low levels of ATM and p27 are
not known, we applied a set of different cut-offs, ranging
from the lower 50% to the lower 5% of the patients in each
cohort (ranked by their expression levels).
Comparison of mutations found (binary variable compari-
sons) between the different groups of patients were per-
formed using Fisher’s Exact Test, while mRNA expression
levels were compared using the ManneWhitney rank test
for independent samples.
Multivariate models were calculated using binary logistic
regression analyses defining mutation status for the different
genes as categorical variables and mRNA expression levels as
continuous variables.
Comparisons between patient groups with respect to
relapse-free survival and disease specific survival were per-
formed by Log-rank tests. For all patients included (both in
the exploratory and in the validation cohorts) follow-up data
for up to 10 years or time of death was available. As for these
calculations, we used the median value of ATM and p27
expression within each cohort as cut-off.
All p-values are given as two-sided, and the p-values ob-
tained by Fischer exact tests are given as cumulative. All sta-
tistical analyses were performed using the SPSS software
version 19 (IBM).3. Results
3.1. Patient cohorts and treatment
This study contains an exploratory cohort consisting of 69 pa-
tients selected from two prospective studies assessing factors
predictive for response to weekly doxorubicin monotherapy
(n ¼ 36) (Geisler et al., 2001) or mitomycin in concert with 5-
fluoro-uracil (n ¼ 33) (Geisler et al., 2003), as outlined in mate-
rials and methods and Figure 2.
In addition, we studied a validation cohort, containing 107
patients treated with epirubicin monotherapy on a 3-weekly
basis for locally advanced breast cancer in a prospective study
(Chrisanthar et al., 2008).
Detailed descriptions of these cohorts are given elsewhere
(Chrisanthar et al., 2008; Geisler et al., 2003, 2001; Knappskog
et al., 2012) and in the Supplementary information.
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All findings are summarized in Figure 3 and Supplementary
Tables S3A and S3B. Among the patients included in the
exploratory cohort, we previously reported mutations in
TP53 (L2/L3 domains) or CHEK2 in 12 out of 18 patients with
progressive disease (PD), contrasting 16 out of 51 revealing
an objective response or stable disease upon therapy
(p ¼ 0.0123). This strong link between p53 inactivation and
drug resistance was further corroborated by including ATM
expression levels in the model (association between defects
in the ATM e CHK2 e p53 pathway and PD; p-values varying
between 0.027 and 0.001 depending on the percentile used to
define ATM levels as “low”; p ¼ 0.010, binary logistic multivar-
iate model; Figure 2A; Supplementary Table 4) (Knappskog
et al., 2012).
These findings were confirmed in the validation cohort
(Chrisanthar et al., 2008; Knappskog et al., 2012) where 5 out
of 10 patients with progressive disease harboured mutations
in TP53 (L2/L3 domains) or CHEK2, while corresponding
numbers among therapy responderswere 10 out of 97 patientsFigure 2 e Study design and treatment regimens of included patients. All pa
to biopsy for genetic analyses before commencement of neoadjuvant chemoth
therapy before surgery (CR[ Complete response, PR[ Partial Response,
Information for details). In the exploratory cohort (n[ 69), 36 of the patient
study assessing resistance to treatment with doxorubicin in locally advanced
representative control groups of SD and PR). These patients received week
The remaining 33 patients were from a prospective study assessing resistanc
due to lack of biological material). These patients received mitomycin and F
received epirubicin every third week (four cycles) before clinical evaluation
cycles) in case of an inferior response to the first line treatment. For furthe(p ¼ 0.005). Similar to what was recorded in the exploratory
cohort, including ATM expression strengthened the observed
association (association between defects in the ATMeCHK2e
p53-pathway and PD; p-values varying between 0.186 and
1.66  104 depending on the percentile used to define ATM
levels as “low”; p ¼ 0.007, binary logistic multivariate model;
Figure 4A; Supplementary Table 4) (Knappskog et al., 2012).
Combining the data from the two cohorts, we here found
the correlation between defects in the p53 pathway and resis-
tance to therapy to be strong and robust across all expression
cut-off values applied for ATM (p < 0.001 for all calculations;
Figure 4A).3.3. RB1 mutations and chemoresistance
Previously, we reported a significant association between RB1
mutations and PD in our explorative cohort, revealing RB1mu-
tations to occur among 3 out of 17 patients with PD in
response to anthracycline or mitomycin treatment, contrast-
ing a single mutation among 51 individuals with response to
the therapy (p ¼ 0.046) (Berge et al., 2010).tients were diagnosed with locally advanced breast cancers and subject
erapy. Post therapy, all patients were evaluated for primary response to
SD[ Stable Disease, PD[ Progressive Disease, see Supplementary
s were originally selected from the 90 patients enrolled in a prospective
breast cancer (z selection of all patients with PD along with
ly doxorubicin for 16 weeks or until progressive disease was recorded.
e to mitomycin and 5-fluorouracil (FUMI; y one patient was omitted
UMI every third week (four cycles). Patients in the validation cohort
of response and change of therapy to paclitaxel every third week (four
r information regarding the cohorts, see Supplementary Information.
Figure 3 e Graphical summary of the detected genetic alterations. Each column represent one of the 176 patients analyzed (Exploratory Cohort;
n[ 69 and Validation Cohort; n[ 107) while each row represent one of the analyzed genes in the p53-or the pRB-pathway. Treatment response
and genetic alterations for each individual patient is given as colored squares according to the color-key (bottom panel). A detailed summary of
these findings are listed in Supplementary Tables S3A and S3B.
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rial including one additional patient with PD (Berge et al.,
2010). All findings in individual patients are listed in
Supplementary Table S3. Analyzing this dataset, we found
RB1 mutations in 3 out of 18 tumours with a PD as compared
to 1 out of 51 responders (p ¼ 0.052).
In the Validation Cohort, we found no point mutations in
RB1 (among 30 patients screened for point mutations in the
entire coding region; 10 PD patients and 20 responders).
Analyzing the total data set for intragenetic deletions, we
found defects in 3 out of 107 patients (deletion of exon 1,
exon 2e10 and exon 10, respectively). Among these 3 patients,
2 belonged to the group of 10 patients displaying progressive
disease upon treatment, while 1 was among the 97 therapy re-
sponders (p ¼ 0.023).
Combining these data from the exploratory and the valida-
tion cohorts, we found RB1 defects to be strongly associated
with lack of response to therapy (p ¼ 0.001).3.4. The pRB- pathway and chemoresistance
The pRB protein is inactivated by different cyclin/cdk-
complexes, the most important ones being Cyclin D/cdk4/6
and Cyclin E/cdk2. Both CCNE1 (Cyclin E) and CCND1 (Cyclin
D) are known to be amplified in breast cancers (Sutherland
et al., 2004). In order to assess the impact of alterations poten-
tially inactivating the pRB-pathway, we analyzed for amplifi-
cations of CCND1 and CCNE1, as well as alterations affecting
the most relevant Cyclin-cdk inhibitors:While amplifications of CCND1 were observed in multiple
tumours, no association to treatment response was recorded
in the exploratory or in the validation cohort (Figure 3,
Supplementary Table S3A; p > 0.5). As for CCNE1, we found
this gene to be amplified in 6 tumours (2 of the 18 PD patients
and 4 of the 51 responders) in the exploratory cohort (p > 0.5;
Figure 5). As for the validation Cohort, we observed CCNE1 am-
plifications in 2 of the PD patients and 3 of the responders
(p ¼ 0.068; p ¼ 0.077, both cohorts combined).
Regarding the most important regulator of CyclinD/cdk4-
activity, CDKN2A (encoding p16), we found 6 patients in the
exploratory cohort to harbour mutations or promoter methyl-
ation affecting this gene (Figure 3, Supplementary Table S3A),
4 of which were resistant to therapy (p ¼ 0.036). In the valida-
tion cohort, in contrast, we observed alterations (promoter
methylation) in 4 out of 97 responders but no methylation or
mutations in the 10 PD-patients (p ¼ 0.055, both cohorts
combined).
Next, we extended our analysis to alterations of CyclinE in-
hibitors. We have previously shown mutations or SNPs
affecting CDKN1A (encoding p21 and p21B) not to be associ-
ated with chemoresistance (Knappskog et al., 2007;
Staalesen et al., 2004) and therefore focused the present ana-
lyses on the CDKN1B (p27KIP1) locus. We found one patient in
the exploratory cohort to harbour a point mutation affecting
the coding region of p27KIP1, while no hypermethylation of
the CDKN1B promoter was detected in any of the patients.
However, analyzing p27KIP1 for mRNA expression levels, we
found low levels to be significantly associated with lack of
Figure 4 e Correlations between p53-/or pRB-pathway defects and resistance to DNA damaging drugs. (A) Lines representing p-values (Y-axis)
for the correlations between defects in the p53-pathway (TP53 mutations, CHEK2 mutation or low levels of ATM mRNA) and resistance to DNA
damaging drugs in vivo, plotted as a function of different cut-offs applied to define “pathologically” low levels of ATM (X-axis). The percentages
refer to the lower percentile of patients in each cohort. (B) Lines representing p-values (Y-axis) for the correlations between defects in the pRb
pathway (RB1 mutations, Cyclin D or E amplifications, CDKN2A defects or low levels of p27 mRNA) and resistance to DNA damaging drugs
in vivo, plotted as a function of different cut-offs applied to define “pathologically” low levels of p27 (X-axis). Exploratory cohort (Cohort 1; treated
with doxorubicin or 5-FU/mitomycin; yellow line), validation cohort (Cohort 2; treated with epirubicin; blue line) and combined data from cohort
1 and 2 (green line).
M O L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 1 5 5 3e1 5 6 4 1559response to therapy in the exploratory cohort (p ¼ 0.007;
p ¼ 0.005 when restricting the analysis to patients with no
other alterations in the pRB-pathway). In the validation
cohort, p27 expression levels were not significantly associated
with resistance (p > 0.2). However, 5 out of the 6 patients with
PD and no RB1 alteration or CCND1/CCNE1 amplifications dis-
played p27 expression levels below the average of the cohort,
with 2 of these patients displaying expression levels in the
lower 12% of the cohort.Figure 5 e Cyclin E copy number analysis. Representative pictures of Cyc
hybridization (FISH) using Cyclin E specific probe (green) and centromere 1
Cyclin E locus in patient with progressive disease upon 5-FU and mitomyc
progressive disease upon doxorubicin monotherapy treatment. MagnificatioRegarding the data from analyses of factors in the pRB-
pathway in concert, according to the hypothesis that one
“hit” would inactivate the biological function of the pathway
in the tumour cells, we found a strong correlation between
inactivation of the pRB-pathway and resistance to therapy in
our exploratory cohort (p-values ranging from 0.001 to 0.094,
depending on the cut-off value for the definition of “low”
levels of p27 expression; p ¼ 0.003, binary logistic multivariate
model; Figure 4B; Supplementary Table 4).lin E copy number analyses as performed by fluorescence in situ
1 specific probe (red). (A) Normal copy number. (B) Highly amplified
in treatment. (C) Highly amplified Cyclin E locus in patient with
n 6303.
MO L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 1 5 5 3e1 5 6 41560Similarly, we observed a clear, although not always signif-
icant, association between inactivation of the pRB-pathway
and resistance to therapy in the validation cohort (p < 0.3
for all calculations where a cut-off of 20% or lower is used to
define “low” p27 expression levels; p ¼ 0.121, binary logistic
multivariate model; Figure 4B; Supplementary Table 4).
Combining the data from the exploratory and the validation
cohorts, we found a strong and robust association across all
cut-offs applied for p27 expression levels (p < 0.01 for all cal-
culations; Figure 4B).
3.5. Concomitant disturbances in the p53-and pRB-
pathways and chemoresistance
We have previously hypothesized that concomitant inactiva-
tion of the p53-and redundant-pathways may lead to chemo-
resistance toward anthracyclines and mitomycin in breast
cancer (Lønning, 2004). Analyzing our data with respect to
the p53-and pRB-pathway in concert, we found concomitant
inactivation of both pathways to be strongly associated with
therapy resistance in the exploratory cohort (p-values ranging
from 0.008 to 3.9  106 depending on the cut-off values used
to dichotomize ATM and p27 mRNA into “low” versus “high”;
p¼ 0.001, binary logistic multivariatemodel including all vari-
ables; Figure 6A; Supplementary Table 4). Most importantly,
regardless of the cut-offs applied, the two-pathway-hit model
revealed a stronger association to chemoresistance as
compared to either the p53-or the pRB-pathways individually.
Considering our validation cohort, inevitably, the correla-
tions were weaker due to fewer patients in the PD-group
(n ¼ 10), and for some of the high cut-offs applied for ATM
expression, the model was non-significant. However, in gen-
eral the validation cohort strongly supported the findings
from the exploratory cohort, with p-values for the two-
pathway-hit model ranging from 0.068 to 2.6  104 when
applying low ATM cut-off values (<14%) and any cut-off for
p27 levels (p ¼ 0.008, binary logistic multivariate model
including all variables; Figure 6A; Supplementary Table 4).
Finally, analyzing the data from both cohorts combined
with respect to the two-pathway-hit model, we found strong
correlations between concomitant inactivation of the p53-
and pRB-pathways and resistance to therapy (p-values
ranging from 2.4  104 to 1.0  108 depending on the cut-
off values used to dichotomize ATM and p27 mRNA into
“low” versus “high”; Figure 6A; Supplementary Table 4). Calcu-
lating the ROC-curve for this dataset, we found the area under
the curve to be 0.809 (Figure 6B).
3.6. Concomitant disturbances in the p53-and pRB-
pathways and long-term outcome
In addition to the impact of concomitant inactivation of the
p53-and the pRB-pathway on primary resistance to therapy,
we further assessed the impact of the two-pathway-hit model
on long term outcome. While the number of patients within
each cohort is limited for such analyses, there was a clear
trend indicating an inferior relapse-free as well as disease-
specific survival for patients with concomitant inactivation
of both the p53-and the RB-pathway, in both cohorts
(Figure 7). Combining data from both cohorts, we found asignificantly lower relapse free survival (p ¼ 0.004) as well as
disease specific survival (p ¼ 0.013; Figure 7).4. Discussion
Despite much effort, neither single parameters nor gene
expression profiles have been able to identify themechanisms
underlying resistance to chemotherapy in patients (Lonning,
2004; Pollack et al., 2002). In this study, we evaluated the hy-
pothesis postulating that concomitant inactivation of redun-
dant gene cascades (focusing on p53 and pRB) may cause
resistance towards anthracyclines and related compounds in
breast cancer (Lonning et al., 2013).
Previous studies by us (Chrisanthar et al., 2008; Geisler
et al., 2003, 2001) and others (Kandioler-Eckersberger et al.,
2000) have revealed an association between TP53 mutations
and lack of response to anthracyclines. This association was
strengthened by including mutations in the CHEK2 gene
(Chrisanthar et al., 2008) and low ATM expression levels
(Knappskog et al., 2012) to the model. While de The and col-
leagues previously have reported TP53mutations to be associ-
ated with an improved chance of having a complete response
(Bertheau et al., 2007), this was limited to patients receiving
cyclophosphamide at high doses in concert with anthracy-
clines. Among patients receiving anthracyclines without
cyclophosphamide or cyclophosphamide at standard doses,
the chance of having a complete response was lower among
tumours harbouring mutated versus wild-type TP53
(Lehmann-Che et al., 2010).
The fact that defects in the p53 pathway alone were not
fully predictive for anthracycline/mitomycin resistance
made us postulate that redundant pathways act in concert
(Lonning, 2004).While conflicting evidence has linked RB1mu-
tations to enhanced chemosensitivity in experimental models
(Bosco et al., 2004), the role of RB1mutations in vivo, in partic-
ular when acting in concert with p53-defects, may be
different. Based on previous findings revealing RB1mutations
to be associated with anthracycline resistance in primary
(Berge et al., 2010) as well as metastatic (Berge et al., 2011)
breast cancer, the aim of this study was i) to explore alter-
ations in the pRB-pathway with respect to drug resistance,
and ii) most importantly, to explore whether inactivation of
the p53-and pRB- pathways in concert may be a stronger pre-
dictor for anthracycline/mitomycin resistance as compared to
alterations in each individual pathway alone, a “nature’s cor-
ollary” to the pharmacological concept of synthetic lethality
(Farmer et al., 2005).
Although RB1 mutations were rare in our study, we
observed a strong association between such mutations and
resistance to DNA damaging drugs in both cohorts analyzed.
This association was strengthened when defects in key regu-
lators of pRB function were included in the model. While each
individual factor revealed a trend for an association with che-
moresistance, taking these factors in concert into a functional
pathway analysis significantly improved the association.
Similar findings have been reported by others with respect
to other tumour characteristics (Hortobagyi 2013; Oricchio
et al., 2014). The only individual parameter for which no asso-
ciation was recorded was Cyclin D. While the reason for this
Figure 6 e Correlations between the two-pathway-hit model and resistance to DNA damaging drugs. (A) Lines representing p-values for the
correlations between concomitant defects in the p53 and the pRB pathway and resistance to DNA damaging drugs in vivo, plotted as a function of
different cut-offs applied to define “pathologically” low levels of ATM and p27. Exploratory cohort (treated with doxorubicin or 5-FU/mitomycin;
yellow line), validation cohort (treated with epirubicin; blue line), and combined data from both cohorts (green line). (B) ROC-curve for the two-
pathway-hit model, based on the combined data from the exploratory- and the validation cohorts (green line in Figure 6A). TPR: True positive
rate; FPR: False positive rate. The eight points on the ROC-curve corresponds to the eight cut-offs on the x-axis of panel A.
M O L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 1 5 5 3e1 5 6 4 1561difference between Cyclin D and Emay be difficult to pinpoint,
previous studies reported elevated Cyclin D expression to be
associated with an improved prognosis in breast cancer
(Loden et al., 2002; Xu et al., 2013).
Notably, some tumours responded to chemotherapy
despite alterations inactivating both pathways. A likely
explanation for this is that mutations may be present in sub-
clones in the tumour, and that these subclones are large
enough to allow detection in the laboratory, but not large
enough to dominate the changes in tumour size. Another po-
tential scenario could be that the alterations affecting the
two pathways are present in different subclones within the
tumour.
We could not identify defects in both pathways across all
tumours with a PD. Considering that our analyses were
restricted to DNA and the RNA and the multiple mechanisms
by which p53 and pRB can be modified and inactivated post-
translationally (Munro et al., 2012; Toledo et al., 2006), most
likely, some patients may have the analyzed pathways inacti-
vated through mechanisms not yet identified. Interestingly,
two tumours in the validation cohort revealing PD upon ther-
apy harboured non-sense mutations in CHEK2 but no detect-
able defects in the pRB-pathway. Chk2 phosphorylation of
the pRB protein at Ser612 has been reported to activate its
pro-apoptotic function (Inoue et al., 2007) thus, the possibility
exists that CHEK2 non-sense mutations may inactivate pRB
function in addition to inactivating the p53 pathway.
A major advantage of this study is that the doxorubicin
treated patients (w50% of the exploratory cohort) and all the
epirubicin treated patients (validation cohort) were treatedwith anthracycline monotherapy. While the chemotherapy
regimens applied to patients in the exploratory cohort (using
doxorubicin monotherapy for weekly treatment, or mito-
mycin and 5-fluoro-uracil combined) may be considered
archaic, patients in the validation cohort received epirubicin
monotherapy at conventional doses at 3-weekly intervals.
Importantly, our findings, that the same predictive factors
are identified across the different patient cohorts, indicate
these factors may predict primary resistance to anthracy-
clines administered at both low and regular doses to a similar
extent.
Although the main focus of the present work was to assess
the impact of concomitant inactivation of the p53-and the
pRB-pathway on primary response to therapy, the dismal bio-
logical effects of this two-pathway-hit model was further sup-
ported by our findings of a significantly reduced relapse-free
as well as disease-specific survival among patients with both
pathways inactivated.
In conclusion, we show that genetic alterations inactivat-
ing the p53 and pRB functional pathways in concert are asso-
ciated with primary resistance to DNA-damaging drugs as
well as long term outcome in patients with locally advanced
breast cancer. Based on these findings, we propose a model
where in vivo resistance to DNA damaging drugs is dependent
on a “two-pathway-hit”, inactivating both pathways. While
our findings do not provide a complete identification of all fac-
tors potentially associated with anthracycline resistance, we
believe they outline a general model explaining primary resis-
tance to DNA damaging drugs in breast cancer in vivo. Further
studies, using genome-/exome-wide sequencing and
Figure 7 e KaplaneMeier plots illustrating the impact of concomitant inactivation of the p53-and pRB-functional pathways on 10 years relapse-
free survival and disease specific survival. Green lines represent patients with concomitant inactivation (two-pathway-hit). Blue lines represent
patients without concomitant inactivation.
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missing, making this a complete model predicting anthracy-
cline resistance. Further, our findings outline a general con-
ceptual approach that may be applicable when exploring the
mechanisms of resistance against other drugs across different
cancer forms in vivo.Acknowledgements
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